IP Library Granted Patent US 8,034,916
Granted Patent B2
US 8,034,916 · App. 12/581,752 · Granted Oct 11, 2011

Expression control elements from the

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,916
App. No.
12/581,752
Granted
Oct 11, 2011
Kind
B2
Abstract

Compositions and methods for regulating expression of nucleotide sequences of interest in a plant are provided. Compositions include novel nucleic acid molecules, and variants and fragments thereof, for expression control elements isolated from the Lemnaceae ubiquitin, r-histone and chitinase genes. A method for expressing a nucleotide sequence of interest in a plant using the expression control elements disclosed herein is further provided. The method includes introducing into a plant or plant cell or nodule an expression construct comprising an expression control element of the present invention operably linked to a nucleotide sequence of interest. In particular, the compositions and methods find use in enhancing expression of nucleotide sequences of interest in duckweed. Also provided is a novel Lemnaceae signal peptide-encoding sequence and the signal peptide encoded thereby. Where an expression construct of the invention is designed to express a polypeptide of interest, this novel signal peptide-encoding sequence can be included within the expression construct of the invention to provide for extracellular secretion of the encoded polypeptide of interest.

Claims (37)

1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

a) a nucleotide sequence comprising the sequence set forth in SEQ ID NO: 2;

b) a nucleotide sequence comprising at least 350 contiguous nucleotides of the sequence set forth in SEQ ID NO: 2 or 5, wherein said nucleotide sequence initiates transcription in a plant cell, and wherein the nucleotide sequence comprises a TATA box; and

c) a nucleotide sequence comprising a functional fragment having at least 15 contiguous nucleotides of the sequence set forth in SEQ ID NO: 2 or 5, wherein said fragment initiates transcription in a plant cell.

2. An expression construct comprising the nucleic acid molecule of claim 1 .

3. The expression construct of claim 2 , further comprising an operably linked heterologous nucleotide sequence of interest.

4. The expression construct of claim 3 , further comprising an operably linked coding sequence for a signal peptide that directs secretion of a polypeptide encoded by said heterologous nucleotide sequence of interest into culture medium.

5. The expression construct of claim 4 , wherein said signal peptide comprises an amino acid sequence selected from the group consisting of:

a) the sequence set forth in SEQ ID NO:16;

b) a sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:16, wherein said sequence directs secretion of said polypeptide into culture medium; and

c) a functional fragment of the sequence set forth in SEQ ID NO:16, wherein said fragment directs secretion of said polypeptide into culture medium.

6. The expression construct of claim 5 , wherein said coding sequence for said signal peptide comprises a nucleotide sequence selected from the group consisting of:

a) the sequence set forth in SEQ ID NO:15;

b) a sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:15; and

c) a fragment of the sequence set forth in SEQ ID NO:15.

7. The expression construct of claim 3 , wherein said heterologous nucleotide sequence of interest encodes a mammalian polypeptide.

8. The expression construct of claim 7 , wherein said mammalian polypeptide is selected from the group consisting of insulin, growth hormone, α-interferon, β-interferon, β-glucocerebrosidase, β-glucoronidase, retinoblastoma protein, p53 protein, angiostatin, leptin, erythropoietin, granulocyte macrophage colony stimulating factor, plasminogen, monoclonal antibodies, Fab fragments, single chain antibodies, cytokines, receptors, human vaccines, animal vaccines, peptides, serum albumin, and combinations thereof.

9. A plant or plant cell or nodule transformed with the expression construct of claim 2 .

10. The transformed plant or plant cell or nodule of claim 9 , wherein said plant or plant cell or nodule is a monocot.

11. The transformed plant or plant cell or nodule of claim 10 , wherein said monocot is from a genus selected from the group consisting of the genus Spirodela , genus Wolffia , genus Wolfiella , genus Landoltia , and genus Lemna.

12. The transformed plant or plant cell or nodule of claim 10 , wherein said monocot is a member of a species selected from the group consisting of Lemna minor, Lemna miniscula, Lemna aequinoctialis , and Lemna gibba.

13. The transformed plant or plant cell or nodule of claim 9 , wherein said plant or plant cell or nodule is a dicot.

14. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

a) a nucleotide sequence comprising the sequence set forth in SEQ ID NO:8; and

b) a nucleotide sequence comprising a functional fragment of the sequence set forth in SEQ ID NO: 8, wherein said fragment enhances transcription in a plant cell.

15. An expression construct comprising the nucleic acid molecule of claim 14 .

16. The expression construct of claim 15 , further comprising an operably linked promoter of interest.

17. The expression construct of claim 16 , wherein said promoter of interest comprises the nucleotide sequence set forth in SEQ ID NO:5.

18. A method for expressing a nucleotide sequence in a plant or plant cell or nodule, said method comprising introducing into the plant or plant cell or nodule an expression construct, said expression construct comprising an expression control element operably linked to a heterologous nucleotide sequence of interest, wherein said expression control element comprises a nucleotide sequence selected from the group consisting of:

a) a nucleotide sequence comprising the sequence set forth in SEQ ID NO: 2;

b) a nucleotide sequence comprising at least 350 contiguous nucleotides of the sequence set forth in SEQ ID NO: 2 or 5, wherein said nucleotide sequence initiates transcription in a plant cell, and wherein the nucleotide sequence comprises a TATA box; and

c) a nucleotide sequence comprising a functional fragment having at least 15 contiguous nucleotides of the sequence set forth in SEQ ID NO: 2 or 5, wherein said fragment initiates transcription in a plant cell.

19. The method of claim 18 , wherein said expression construct further comprises an operably linked coding sequence for a signal peptide that directs secretion of a polypeptide encoded by said heterologous nucleotide sequence of interest into culture medium.

20. The method of claim 18 , wherein said heterologous nucleotide sequence of interest encodes a mammalian polypeptide.

21. The method of claim 18 , wherein said heterologous nucleotide sequence of interest comprises plant-preferred codons in the coding sequence for said heterologous nucleotide sequence of interest.

22. The expression construct of claim 5 , wherein said heterologous nucleotide sequence of interest encodes a mammalian polypeptide.

23. The expression construct of claim 22 , wherein said mammalian polypeptide is selected from the group consisting of insulin, growth hormone, α-interferon, β-interferon, β-glucocerebrosidase, β-glucoronidase, retinoblastoma protein, p53 protein, angiostatin, leptin, erythropoietin, granulocyte macrophage colony stimulating factor, plasminogen, monoclonal antibodies, Fab fragments, single chain antibodies, cytokines, receptors, human vaccines, animal vaccines, peptides, serum albumin, and combinations thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: BIOLEX THERAPEUTICS, INC.
To: SYNTHON BIOPHARMACEUTICALS B.V.
Reel/Frame 028278/0729 →
RELEASE OF SECURITY INTEREST Recorded May 21, 2012
From: MIDCAP FINANCIAL SBIC, LP
To: BIOLEX THERAPEUTICS, INC.
Reel/Frame 028276/0548 →
SECURITY AGREEMENT Recorded Nov 9, 2010
From: BIOLEX THERAPEUTICS, INC.
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 025333/0026 →